Puretech Health plc (PRTC) Ordinary 1p
- Add to watchlist
- Create an alert
- This stock can be held in a
n/a
n/a
238.50p
£370.62 million
154.80p
n/a
139.00p
n/a
1.60p (1.02%) Previous:
1.60p
n/a
n/a
2,000
Performance
1 week 1W | 3.25% | 1 year 1Y | 15.13% |
---|---|---|---|
1 month 1M | 9.58% | 2 years 2Y | 41.58% |
3 months 3M | 9.17% | 3 years 3Y | 46.53% |
6 months 6M | 21.98% | 5 years 5Y | 48.74% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 3.33 | 15.62 |
Profit before tax ($m) | (36.10) | (92.78) |
Adjusted EPS (¢): | (24.00) | (18.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
London close: Stocks weaker ahead of key central bank decisions
16 December 2024 15:35
-
PureTech hails "exciting" results from lung disease trial
16 December 2024 09:30
-
London close: Stocks give up gains to finish in the red
21 October 2024 15:48
-
PRTC's Ph2b in IPF Successful; New SOC Potential
16 December 2024 07:00
-
Holding(s) in Company
11 December 2024 17:30
-
PRTC's Seaport Presents Ph1 SPT-300 Data at ACNP
11 December 2024 12:05
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.